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BACKGROUND: Impact assessment of community-based 
ivermectin treatment control of onchocerciasis is required to 
determine its effectiveness. This study was conducted to evaluate 
geographic coverage and demographic ivermectin treatment 
compliance. 
METHODS: The number of village dosage were obtained from the 
community based distributors. Bioclinical data of participants 
comprising gender, age, number of treatment received from 
inception and dosage were obtained. Each participant was 
subjected to physical examination for palpable nodule and other 
skin clinical signs and symptoms of onchocerciasis. Visual acuity 
test was done using the Snellen illiterate E-chart. Eye examination 
was performed using touch loop and handheld ophthalmoscope. 
Skin snips from both iliac crests were incubated overnight at 28-
32ºC and emerged micrifilaria enumerated under an inverted 
microscope. The changes in epidemiological indices at post-decade 
of mass drug administration were compared with baseline data. 
RESULTS: Village annual ivermectin treatment doses averaged 
62%, ranging between 10-100%. Individual treatment compliance 
rate was generally low with an average of 4 treatments and a range 
between 0-10. Despite variations in treatment compliance, there 
were significant improvements in some onchocercal morbidities. 
These include reduced number and severity of itching, visual 
impairment, papular onchodermatitis, onchocercomata (palpable 
nodules) and leopard skin. Ivermectin treatment halted 
development of new blind cases, except the case of a man who had 
optic nerve disease and became blind 2 years after ivermectin 
treatment had commenced. There was a significant overall 
reduction in parasite burden with very low mean skin microfilaria 
load of 1.7mf per skin snip and 3.7% skin mf prevalence, compared 
to baseline data of 17.7mf and 37.9% respectively. The palpable 
nodule was also drastically reduced from 14.5% to 6.4%. Outcome 
of this study has practically demonstrated that even a single dose 
ivermectin treatment is capable of clearing skin mf load on a long-
term basis. This assertion is exemplified by the result obtained from 
Bomjock village that had taken treatment only at inception, and the 
prevalence rate was reduced from 70% to about 9.0% at post-
decade of intervention. 
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CONCLUSION: It can be inferred that high 
demographic coverage with annual treatment 
doses, it is feasible to attain a shorter time 
(within a decade) contrary to the anticipated 
longer-term projection. 
KEYWORDS: Ivermectin, Microfilaria, 
Treatment Compliance, Onchocerciasis, 




Concerted efforts to control onchocerciasis had 
relied on strategies directed at reducing or 
eliminating the vector using insecticides 
(larvicides). Its setback includes the vast 
landmass, negative environmental effects and 
huge costs to sustain the project (1).  Secondly, 
two drugs, diethyl carbamazine (DEC) and 
suramin available for treatment were very toxic.  
Thirdly, nodulectomy campaign embarked  upon 
to eliminate adult worms could not achieve the 
desired results because not all nodules can be 
detected by palpation as cryptic infections made 
this control approach not feasible. A foreseeable 
effective and affordable control strategy emerged 
when ivermectin previously patented for 
veterinary use was proven to have microfilaricidal 
activity (2).  More importantly, the drug was not 
found associated with serious side effects and 
therefore suited its use as mass drug 
administration (MDA) through mass distribution 
to endemic rural and often remote human 
settlements. Prior to implementing MDA with 
Mectizan or ivermectin or Stromector, over 40 
million Nigerians were exposed to 
Onchocerciasis; 20 million were infected and 
about 120,000 went blind from the disease (3). 
Coincidentally, most of the people infected or at 
risk of infection were poor peasant farmers who 
cannot afford the drug and have no access to 
health facility.  Therefore, the development of a 
novel control strategy called community directed 
treatment with ivermectin (ComDTI) was highly 
welcome. With the biannual treatment strategy 
adopted in six Latin American onchocerciasis 
endemic countries have proved adequate in 
eliminating the disease (4,5) within a record time 
frame. 
Annual distribution of Mectizan started in 
Nigeria in 1992 under the National Primary Health 
Care.  The study area comprised six farming 
villages located within onchocerciasis meso-
endemic focus as described (6).  The villages were 
enlisted into the National Mectizan Distribution 
Program in 1994.  Before the commencement of 
ivermectin distribution in the study villages, 
baseline data on prevalence and intensity of 
onchocercal related clinical manifestations, 
parasitological (skin microfilarial load and 
presence of palpable nodule) were obtained (7).  
Various epidemiological mathematical models 
have been designed to project the duration for 
treatment that may likely achieve the eradication 
of onchocerciasis. Among them are the projection 
by ONCHOSIM (onchocerciasis simulation 
model), a microsimulation mathematical model of 
the dynamics of onchocerciasis transmission, to 
explore the potentials of a hypothetical 
macrofilaricidal drug for the elimination of 
onchocerciasis under different epidemiological 
conditions (8). In all cases, a 10-year programme 
of annual macrofilariciding was considered. A 
modelling stimulation SIMON also predicted that 
between 10-15 years will be needed to attain 
eradication of mf (9). Just as it was earlier 
envisaged, treatment was required to last beyond 
the adult life span estimated to be between 9-15 
years.  According to Plaiser et al. and Turner et al. 
(10,11), the ONCHOSIM and the epidemiology of 
onchocerciasis (EPIONCHO) both projected that 
in mesoendemic areas, the provisional operational 
threshold for treatment interruption followed by 
surveillance (pOTTIS) can be reached with annual 
treatment. The strategy may be insufficient in very 
highly hyperendemic areas, or would require 
prolonged continuation of treatment (12). Thus, 
the principal challenge for onchocerciasis control 
is to deliver ivermectin treatment to all target 
communities and to sustain high treatment 
coverage over a very long period (13).  Therefore, 
the need to evaluate the long-term impact of 
ComDTI on public health and the transmission 
potential based on host parasite reservoir is 
imperative (14). Monitoring is a key issue to 
ascertain the level of treatment compliance that 
would impact on this control strategy. More 
importantly, the observed continued transmission 
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after a decade of ivermectin treatment intervention 
in Cameroon (15) and the clear evidence of 
onchocerciasis elimination in parts of Senegal and 
Mali, and in Nigeria as variously reported 
(16,17,18) showed that annual ivermectin 
treatment can effectively be used in the 
eradication of onchocerciasis. Impact of different 
levels of compliance to treatment at post decade of 
MDA on skin mf load, nodule rate and clinical 
(eye and skin) manifestations is presented in this 
report.  
 
MATERIALS AND METHODS 
 
Study area and sample population: The study 
area included ten villages within Gurara river 
basin of Kachia Local Government Area (LGA) of 
Kaduna State, Nigeria.  Six sentinel villages had 
baseline data while four control villages were 
without baseline data. The area is within latitude 
9 37' to 9 45’ N and longitude 7 40' to 8 E. 
The sample population (n=438) from the sentinel 
communities was comprised of males (n=220) and 
females (n=218) drawn from among the pre-
baseline sample population. Only those who 
voluntarily consented to participate were 
examined for skin diseases (including palpation 
for nodule and skin snipping), and were subjected 
to visual acuity test for each eye. Subjects were 
between the ages of 14-90 years. The control 
study population (n=194) was made up of males 
(n=90) and females (n=104) between the ages of 
15-90 years. Unlike the others, Ibika community 
was farther away from the study area and was 
excluded from the MDA at inception based on the 
outcome of the rapid epidemiological mapping of 
onchocerciasis (REMO) that was conducted.  
Experimental design: Emerged microfilariae 
from skin snips taken from both iliac crests were 
incubated at ambient temperature between 28-
32ºC over night and enumerated under inverted 
microscope using tally counter.  Each patient was 
examined for skin clinical manifestations 
according to Murdoch et al. (19), and visual acuity 
(VA) for each eye was assessed using illiterate E-
chart and counting of fingers at 6 and 3 meter 
distance. Eye examination was performed using 
touch loop and handheld ophthalmoscope. The 
number of treatment taken and reasons for not 
taking the treatment were obtained from 
individuals. Information on the number of annual 
treatment administered to the village was obtained 
from the community based distributors and 
compared to information provided by the village 
heads. 
Ethics: This project was approved by the 
Research and Development Committee of the 
Nigerian Institute for Trypanosomiasis (and 
Onchocerciasis) Research. All procedures in the 
collection of human samples were obtained in 
accordance to the Helsinki Declaration of 1975 (as 
revised in 1983). The villagers were briefed in 
their local dialect, and only those who volunteered 





The number of persons (n=438) who voluntarily 
participated and were examined in this long-term 
follow-up study at 10 years after commencement 
of ivermectin treatment intervention represented 
about 80% of the baseline sample population. 
Only few participants (2.5%) of the sample 
population immigrated into the study area within 
the period of 1994 to 2003. The number of 
emigrants could not be assessed. There was low 
level of annual Mectizan
®
 distribution to some 
villages. The rate of non-compliance, which 
include persons who did not take any ivermectin 
were 17.5% (n=65) while 82.5% (n=373) of the 
sample population (n=438) had taken one or more 
doses. There was a decrease from the number of 
persons who received one dose 17% followed by 
those that received 2 and 4 doses with 15.9% 
(n=59), and only one person (0.3%) received 9 
doses (Figure 1). 
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Figure 1: Distribution of annual ivermectin (Mectizan
®
) treatment compliance. Participants who did not 
take ivermectin are the non-compliant (0) and those who took between 1-9 doses are the compliant. 
 
At the time of this study, the villages that were 
expected to have taken ten annual treatments from 
1994-2003 had mean of 6.2 (62%) doses with a 
range of 1 (10%) to 10 (100%).  One of the 
sentinel villages, Bomjock, had one treatment dose 
at the inception of Mectizan
® 
distribution within 
the study area in 1994.  Kurmin Gwaza and 
Angwar Maisaje had 4, Gidan Tama had 10 and 
others had 8.  By implication, the individual 
compliance rates in the 6 sentinel villages were 
generally very low as shown on Table 1.  The 
average ranging between 7.0 to 78.7 treatment 
compliance and percentage doses taken were 
82.4±6.3% and 34.3%, respectively. Those with 
palpable nodules were 28(6.4%) and 16(3.7%) 
microfilaria prevalence in the sentinel sites 
(n=438). Microfilaria was not seen in Sabon 
Gantan (n=100) and Gidan Tama (n=61), 
1(1.56%) case in Kurmin Gwaza (n=64), 3(4.47%) 
in Gantan (n=68); 5(7.69%) in Ungwan Shaho 
(n=65) and 7(9.0%) in Bomjock (n=80).  The 
highest skin microfilaria load was 18 per snip. The 
changes in parasitological data when compared 
with baseline data are shown in Table 2. There 
was a significant reduction (p<0.05) in skin 
microfilaria prevalence from 201(37.9%) pre-
treatment baseline compared to 17(4.6%) at post-
decade of MDA. Similarly, skin mf density, 
community microfilaria load and palpable nodule 
were significantly reduced (p<0.05) from 
77(14.5%) to 28(6.4%). The palpable nodule rate 
and skin microfilaria prevalence did not show any 
strong correlation with both age and number of 
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Treatment compliance Prevalence rates (%) 
A. Sentinel   Population 
coverage δ (%) 
Percentage 
doses § 
Nodule Skin mf 
Bomjock 80 1 45 (56.3) 7.0 5 (6.3) 7 (8.75) 
Gidan Tama 61 10 57 (93.4) 78.7 9 (14.8) 0 
Ungwar Shaho 65 8 57 (87.7) 40.3 6 (9.4) 5 (7.8) 
Kurmin Gwaza 64 4 53 (82.8) 22.7 4 (6.0) 1 (1.49) 
Gatan 68 10 54 (79.4) 18.5 1 (1.5) 3 (4.54) 
Sabon Gatan 100 7 95 (95.0) 38.5 3 (3.0) 0 
Total (Mean±Stdev) 438 6.7 361 (82.4±6.3) 34.3±21.4 28 (6.8±4.8) 16 (3.8±3.0) 
B. Control Villages       
Rami Kura* 42 2 12 (28.6) 3.6 6 (14.3) 1 (2.38) 
Ungwar Maisaje* 57 10 48 (84.2) 20.5 2 (3.5) 0 
Ungwar Kongo* 33 9 23 (69.7) 20.0 7 (21.2) 0 
Ibika 62 0 1 (1.6) 0 3 (4.8) 0 
Sub-total 194 5.3       84 (43.3±32.8) 11.0±9.3) 18 (9.3±7.2) 1 (0.5) 
Total (Mean±Stdev) 632 6.1 445 (67.8±30.8)) 25.0±23.1 46 (8.5±6.4) 17 (2.5±3.4) 
 
The sign δ represent sample sizes that took 1-9 
Mectizan
®
 treatment doses. The percentage values 
of total actual doses divided by total expected 
doses of the sample population (§). *These control 
villages were enlisted for mass drug 
administration but had no baseline data. Standard 
deviation from mean (Stdev). 
 
Table 2: Comparing baseline with post-decade treatment parasitological data 
 
 
























Reduced mf due to clearance. 
Skin mf density 17.7 1.7 p<0.05 Effect on female  fecundity to 
release mf. 
 





























Probable remission of nodules 
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Moderate or not too serious form of itching was 
the main complaint among 14.8% (n=55), and few 
patients claimed that it was more intense after 
ivermectin treatment.  Eight persons (2.2%) had 
leopard skin, and few, 15(4.0%), showed one or 
more forms of onchocercal skin changes as shown 
in Table 3.  They include papular onchocercal 
dermatitis, chronic onchocercal dermatitis, 2; 
hernia, 3; a case of elephantiasis of the scrotum at 
the earlier stage of development.  Thirty persons 
(8.0%) had visual impairment based on VA of 
6/18 and above, with 2 partial and 7 total blind 
cases (2.4%) which included one new blind case.  
Moderate or not too serious form of itching was 
the main complaint among 23.53% (n=60) of the 
four control villages.  Five persons (1.96%) had 
leopard skin, and few, 10(4.0%), showed one or 
more forms of onchocercal related skin changes. 
Twenty-five persons (9.8%) had visual 
impairment based on VA of 6/18 and above. Most 
cases of blindness were due to accident, old age 
and childhood disease.  Those with palpable 
nodules were 24(9.41%), and the microfilariae 
prevalence of the control sample population was 
1(0.4%) with 18 and 7 microfilariae per right and 
left iliac skin snip respectively. 
Among the post-decade onchocercal related 
skin manifestations such as onchodermatitis, 
leopard skin and the ocular clinical symptoms of 
poor visual impairment and blindness were 
significantly higher (p<0.05) in sentinel villages 
compared with control villages. Unlike the 
sentinel villages, all cases of blindness in the 
control villages were not due to onchocercal 
related causes. Evidence of itching of 14.8% 
(n=55) and palpable nodule rate 28(6.4%) in 
sentinel villages were lower compared with 
23.53% (n=60) and 9.41% (n=24) recorded in 
control villages. Observed differences were not 
statistically significant (p>0.05). However, the 
skin mf prevalence was significantly higher 
(p<0.05) in the sentinel villages than in the control 
villages with 17 (4.6%) versus 1 (0.4%), 
respectively. The only microfilaria positive case 
was in a 35-year-old male who had taken 
ivermectin twice. A case of an individual with 
nine palpable nodule without any skin microfilaria 
took Mectizan four months before the study. 
 
Table 3: Comparing baseline with post-treatment clinical data 
The probability values (p<0.05) show statistical significance by unequalled data t-test. Figures in 
parenthesis are percentages.  
 

















Decrease in overall 
skin clinical signs 
Itching 382 (72) 55 (14.8) Significant 
(p<0.05) 




38 (7.2) 2 (0.5) Significant 
(p<0.05) 
Remission of 
reactive skin rashes 
Chronic 
Onchodermatitis 
26 (4.9) 2 (0.5) Significant 
(p<0.05) 
Remission of chronic 
rashes 
Leopard Skin 10 (1.9) 14 (3.8) Significant Increase in leopard 
skin 
Visual Impairment 
VA of 6/18 & above 




vision and eye 
lesions 




development of new 
blind cases 
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Assessment of the long term impact of annual 
ivermectin treatment of endemic communities is 
needed to determine the feasibility of controlling 
and eventually eradicating onchocerciasis. The 
impact of ComDTI on public health in 
onchocerciasis endemic communities has been 
reported to be impressive (20,21,22). It was 
observed that the skin clinical symptoms including 
palpable nodules dropped over the base line 
figures. Many expressed having been relieved 
from severe skin itching which was widespread 
before the Mectizan distribution started in these 
areas. The few who experienced itching reaction 
did not report any serious limitations to warrant 
discontinuing with treatment. 
These results were in total contrast to 
baseline figures which ranges between 25-72% for 
the villages (7). In addition to this impressive 
performance by the drug, it seems that the fear that 
non-compliance may adversely affect the control 
method may not be a serious problem as hitherto 
assumed. The absence of infection and clinical 
manifestations among the younger age group 
below 30 years was a confirmation of a possible 
break in disease transmission cycle. An early 
study undertaken by Boussinesq et al. (23) showed 
that the pretreatment community microfilarial 
loads (CMFL) decreased from 5.5 and 25.1 
microfilariae per snip after 32 months to only 24 
and 51% of the initial values, respectively. In a 
third village treated once had the mean 
microfilaria density 28 months after treatment to 
be only 12% of the initial value. 
From our finding, the incidence of visual 
impairment showed remarkable increase over 
those of baseline data. This could be attributed to 
the fact that those hitherto seen to have one form 
of eye lesion now manifest as poor visual acuity. 
Just like the only new case of blindness recorded 
was in a man who was said to be blind 2 years 
after the treatment started.  This is not unexpected 
as non-reversible lesion will not be affected by 
treatment (24,25). The patient already had optic 
nerve disease before treatment started. Another 
notable observation was the claim of 
disappearance of nodules and remarkable 
improvement in severity of itching. A typical case 
was that of a man who claimed that the severity of 
the leopard skin had improved along with reduced 
severe itching. Similar findings have been 
documented in other studies by Ogbuagu et al. and 
Emuka et al. (26,27). This is contrary to report 
(28) that after three doses, 44% of the patients 
remained skin snip positive. A long term effect of 
the treatment was not assessed. 
It is plausible for the continued presence of 
palpable nodules and skin microfilaria despite 
varied annual ivermectin treatment doses to be 
attributed to sub-optimal responses. Elsewhere, 
inability to clear mf from skin after multiple 
treatments has been documented (29). It is worth 
mentioning that the low prevalence and skin mf 
density especially among inhabitants of Bomjock 
which had only received one treatment  proved the 
long term efficacy of single dose ivermectin. 
Whether this could be attributed to reduce 
turnover of microfilaria production and release, or 
increased and sustained microfilaria elimination 
on the part of the host as suggested by Schulz-key 
and Karam (30) remained subjective.  Another 
possibility is to suspect the role of partial drug-
facilitated cell mediated immunity may play in 
preventing microfilariae from repopulating the 
skin on a long-term basis.  Should that be the case, 
it will be an added advantage previously not 
anticipated when ivermectin treatment of 
onchocerciasis was approved for field use. 
Earlier reports have documented delay in 
repopulation between 9-12 months (31). Due to 
lack of suitable model host for laboratory study, 
the high cost and ethical consideration for 
subjecting humans to placebo trial for up to ten 
years have precluded determination of the 
outcome of a single treatment. It has been 
documented by Pacque et al. (32) that up to 33% 
of patients in non-endemic areas were cured with 
only 1 dose of ivermectin. Thus, the study of 
treatment compliance rate after a decade of 
intervention and the observed impact of single 
dose treatment on skin mf load and nodule rates 
clearly support the efficacy of single-dose 
treatment.  
It was feared that non-compliance to regular 
annual treatment will seriously jeopardize the 
attainment of the set target or objective (33,34).  
An astonishing finding that despite receiving only 
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one and few treatment doses, onchocerciasis 
prevalence was drastically reduced from 72% to 
9% in Bomjock and overall. The same applies to 
the infection intensity. The precarious public 
health situation of river blindness in these villages 
within the Gurara river basin was being mitigated.   
Moreover, black fly uptake of mf has been shown 
not to be associated with the level of skin mf 
density (8). Therefore, the surrounding villages 
need to be enlisted for treatment to avert few 
pockets of few infected individuals serving as 
reservoir of infection.Yet, a panacea for effective 
control based on ComDTI is to attain 100% 
geographic coverage and at least 50% individual 
treatment compliance. The mechanism of 
sustained elimination of parasite reservoir may be 
accomplished if compliance rate is improved (35). 
It will require advocacy visits to mobilize the 
people to comply with annual treatment.  
The outcome of this study has confirmed that 
repopulation of skin with mf may just be a 
transient features observed immediately after 
treatment. The long term impact of treatment 
could have resulted in clearing skin mf and 
remission of nodules as observed in this study. It 
has been reported by Pion et al. and Basáñez et al. 
(36,37) that O. volvulus microfilaria density 
measured after a first treatment with ivermectin, 
and thus probably the rate of skin repopulation by 
microfilariae (mf) varies according to several host 
factors. A mathematical model (38) had predicted 
reduction in microfilaridermia  by 98–99% after 
1–2 months treatment, which corresponds to the 
time when the fraction of females harbouring live 
microfilariae were at the lowest (reduced by 
around 70% from its original value). 
The isolated mf positive case that was 
recorded in Rami Kura in a 35-year-old man who 
had taken 2 doses of Mectizan calls for concern. 
Whether this was a case of non-responder as 
observed (29) or resistance to ivermectin as 
suggested by Osei-Atweneboana et al. (39) 
remained unknown. This study has confirmed that 
the adjoining villages do not pose any threat of 
serving as reservoir of infection for re-invasion of 
endemic areas after post control.  Interestingly, the 
case of the young boy with 9 nodules but without 
skin mf is a typical example.  He took treatment 
that year before the screening exercise. 
Inference drawn from this study holds a 
contrary opinion to the predicted duration required 
to attain elimination of mf, as suggested via 
mathematical model EPIONCHO, which proposed 
that it will only be achievable within 25 years for 
the setting with 51% baseline mf prevalence (40). 
Annual ivermectin mass treatment strategy may 
not require longer continuation to achieve the 
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